Generic Pathway For Biologics Weighed At Hearing

Law360, New York (March 9, 2007, 12:00 AM EST) -- Generic versions of biologic drugs are either a safe and less expensive alternative or could pose a sizable risk to patient safety, depending on whose testimony you believed at a committee hearing in the U.S. Senate on Thursday.

The Senate Health, Education, Labor and Pensions Committee held a hearing Thursday about follow-on biologics as legislators mull bills proposed in both the U.S. House of Representatives and the Senate that would give the U.S. Food and Drug Administration the discretion to decide when it is scientifically appropriate...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.